A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs TG 1050 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Transgene
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 23 Oct 2017 According to a Transgene media release, a poster describing the first promising clinical data was presented at the at the annual meeting of the AASLD (American Association for the Study of Liver Diseases) 2017.
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Transgene media release.